Skip to main content

Table 2 Treatment characteristics by second-line treatment group

From: Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

 

Chemotherapy only N = 38

Cetuximab N = 38

Bevacizumab N = 106

Total N = 182

Regimen used in 1st line therapy, n (%)

    

Oxaliplatin based

5 (13%)

4 (11%)

54 (51%)

63 (35%)

Irinotecan based

21 (55%)

28 (74%)

40 (38%)

89 (49%)

Neither Oxaliplatin nor Irinotecan based

12 (32%)

6 (16%)

12 (11%)

30 (16%)

Regimen used in 2nd line therapy, n (%)

    

5-FU

0 (0.0%)

0 (0.0%)

1 (0.9%)

1 (0.5%)

5-FU / AMG 706 / Irinotecan / Leucovorin

1 (2.6%)

0 (0.0%)

0 (0.0%)

1 (0.5%)

5-FU / Gamma Interferon / Irinotecan / Leucovorin

0 (0.0%)

0 (0.0%)

1 (0.9%)

1 (0.5%)

5-FU / Gamma Interferon / Leucovorin

2 (5.3%)

0 (0.0%)

0 (0.0%)

2 (1.1%)

5-FU / Interferon / Leucovorin

2 (5.3%)

0 (0.0%)

0 (0.0%)

2 (1.1%)

5-FU / Irinotecan / Leucovorin

6 (15.8%)

13 (34.2%)

29 (27.4%)

48 (26.4%)

5-FU / Irinotecan / Leucovorin / Oxaliplatin

0 (0.0%)

0 (0.0%)

5 (4.7%)

5 (2.7%)

5-FU / Irinotecan / Leucovorin / Oxaliplatin / Capecitabine

0 (0.0%)

0 (0.0%)

2 (1.9%)

2 (1.1%)

5-FU / Irinotecan / Leucovorin / Capecitabine

2 (5.3%)

0 (0.0%)

4 (3.8%)

6 (3.3%)

5-FU / Leucovorin

2 (5.3%)

1 (2.6%)

3 (2.8%)

6 (3.3%)

5-FU / Leucovorin / Oxaliplatin

3 (7.9%)

3 (7.9%)

38 (35.8%)

44 (24.2%)

5-FU / Leucovorin / Oxaliplatin / Capecitabine

0 (0.0%)

0 (0.0%)

1 (0.9%)

1 (0.5%)

Bevacizumab Only

0 (0.0%)

0 (0.0%)

2 (1.9%)

2 (1.1%)

Cetuximab Only

0 (0.0%)

4 (10.5%)

0 (0.0%)

4 (2.2%)

Floxuridine / Irinotecan

1 (2.6%)

0 (0.0%)

0 (0.0%)

1 (0.5%)

Irinotecan

11 (28.9%)

13 (34.2%)

3 (2.8%)

27 (14.8%)

Irinotecan / Oxaliplatin / Capecitabine

0 (0.0%)

0 (0.0%)

1 (0.9%)

1 (0.5%)

Irinotecan / Capecitabine

0 (0.0%)

2 (5.3%)

3 (2.8%)

5 (2.7%)

Oxaliplatin / Capecitabine

2 (5.3%)

1 (2.6%)

7 (6.6%)

10 (5.5%)

Capecitabine

6 (15.8%)

1 (2.6%)

6 (5.7%)

13 (7.1%)